Original Article Clinical and pathological comparison of Budd-chiari syndrome associated hepatocellular carcinoma and HBV-associated hepatocellular carcinoma

Xiaowei Dang, Luhao Li, Lin Li, Suxin Li, Peiqin Xu
2016 Int J Clin Exp Med   unpublished
Objective: This study was to compare the pathological changes and postoperative survival time between patients with Budd-Chiari syndrome (B-CS) associated hepatocellular carcinoma (HCC) and those with hepatitis B virus (HBV) associated HCC. Methods: 15 B-CS-associated HCC and 30 HBV-associated HCC patients undergoing operation were analyzed. Results: The average Ki67 index of B-CS-associated HCC group (19.7±14.2) was significantly lower than that of HBV-associated HCC group (31.2±18.0)
more » ... 31.2±18.0) (P=0.037). However, regarding the positive expression rate of CD34 and Glypican-3, our study did not find out any significant difference between the two groups (73.3% vs 83.3%, P=0.693; 86.7% vs 76.7%, P=0.693). There were also no significant differences in the pathological grade and clinical stage between both groups. Moreover, One-year, two-year and three-year survival rates of B-CS associated HCC patients were 93.3%, 80.0% and 41.6% respectively after surgery, compared with 86.3%, 75.5% and 20.7% in those HBV associated HCC patients (P<0.05). Conclusions: The malignant degree of B-CS-associated HCC may not be lower than that of HBV-associated HCC. However, the survival time of the former is significantly longer than that of the latter after resection.